People

Central Nervous System

Brain-related illness afflicts more than 1.5 billion people worldwide. Companies selling neuropharmaceutical products generated over $93 billion in global revenues in 2005 and represent the top selling category of drugs in the world. These markets can be broken down into the following categories:

BCI is focusing its initial efforts on the treatment of mood disorders and believes its technology has applications in other neuropharmaceutical markets such as cognition, schizophrenia and brain repair.

Mood Disorders

The worldwide market for pharmaceuticals to treat depression and anxiety exceeds $30 billion. 10% of all adults have some sort of mood disorder. Approximately one-third of patients do not respond to currently available therapies to treat anxiety and depression. In addition, current therapies generally have a 3-6 week delay for onset of action, and patients often suffer from gastrointestinal or sexual side effects. BCI believes there is a significant opportunity for a novel therapy with a unique mechanism of action for the treatment of depression and anxiety.